Polypharmacy and frailty in chronic kidney disease

Hidemi Takeuchi; Haruhito Adam Uchida; Jun Wada

doi:10.1007/978-981-15-2365-6_14

Polypharmacy and frailty in chronic kidney disease

Hidemi Takeuchi, Haruhito Adam Uchida, Jun Wada

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

The prognoses of various diseases have improved because of progress in the field of medicine and clinical practice guidelines developed in countries around the world. However, polypharmacy and frailty have become a global public health concern because of the increase in longevity. Although polypharmacy and frailty are associated with a broad range of negative outcomes, they occur concurrently in patients with chronic kidney disease (CKD) at a higher rate. Elderly patients with CKD usually require multiple medications to prevent CKD progression and complications, and their conditions are generally complicated. In this article, we outline polypharmacy and frailty, which frequently occur in patients with CKD and introduce notes and approaches to overcome these issues.

Original language	English
Title of host publication	Recent Advances of Sarcopenia and Frailty in CKD
Publisher	Springer Singapore
Pages	223-237
Number of pages	15
ISBN (Electronic)	9789811523656
ISBN (Print)	9789811523649
DOIs	https://doi.org/10.1007/978-981-15-2365-6_14
Publication status	Published - Jan 1 2020

Keywords

ADEs prescribing cascade
ADRs
CKD
Elderly
Frailty
Multimorbidity
PIMs
Polypharmacy

ASJC Scopus subject areas

Medicine(all)

UN SDGs

This output contributes to the following Sustainable Development Goal(s)

Access to Document

10.1007/978-981-15-2365-6_14

Fingerprint Dive into the research topics of 'Polypharmacy and frailty in chronic kidney disease'. Together they form a unique fingerprint.

Cite this

@inbook{7f2f811a490e4e07b2779b39b4e8350b,

title = "Polypharmacy and frailty in chronic kidney disease",

abstract = "The prognoses of various diseases have improved because of progress in the field of medicine and clinical practice guidelines developed in countries around the world. However, polypharmacy and frailty have become a global public health concern because of the increase in longevity. Although polypharmacy and frailty are associated with a broad range of negative outcomes, they occur concurrently in patients with chronic kidney disease (CKD) at a higher rate. Elderly patients with CKD usually require multiple medications to prevent CKD progression and complications, and their conditions are generally complicated. In this article, we outline polypharmacy and frailty, which frequently occur in patients with CKD and introduce notes and approaches to overcome these issues.",

keywords = "ADEs prescribing cascade, ADRs, CKD, Elderly, Frailty, Multimorbidity, PIMs, Polypharmacy",

author = "Hidemi Takeuchi and Uchida, {Haruhito Adam} and Jun Wada",

year = "2020",

month = jan,

day = "1",

doi = "10.1007/978-981-15-2365-6_14",

language = "English",

isbn = "9789811523649",

pages = "223--237",

booktitle = "Recent Advances of Sarcopenia and Frailty in CKD",

publisher = "Springer Singapore",

}

TY - CHAP

T1 - Polypharmacy and frailty in chronic kidney disease

AU - Takeuchi, Hidemi

AU - Uchida, Haruhito Adam

AU - Wada, Jun

PY - 2020/1/1

Y1 - 2020/1/1

N2 - The prognoses of various diseases have improved because of progress in the field of medicine and clinical practice guidelines developed in countries around the world. However, polypharmacy and frailty have become a global public health concern because of the increase in longevity. Although polypharmacy and frailty are associated with a broad range of negative outcomes, they occur concurrently in patients with chronic kidney disease (CKD) at a higher rate. Elderly patients with CKD usually require multiple medications to prevent CKD progression and complications, and their conditions are generally complicated. In this article, we outline polypharmacy and frailty, which frequently occur in patients with CKD and introduce notes and approaches to overcome these issues.

AB - The prognoses of various diseases have improved because of progress in the field of medicine and clinical practice guidelines developed in countries around the world. However, polypharmacy and frailty have become a global public health concern because of the increase in longevity. Although polypharmacy and frailty are associated with a broad range of negative outcomes, they occur concurrently in patients with chronic kidney disease (CKD) at a higher rate. Elderly patients with CKD usually require multiple medications to prevent CKD progression and complications, and their conditions are generally complicated. In this article, we outline polypharmacy and frailty, which frequently occur in patients with CKD and introduce notes and approaches to overcome these issues.

KW - ADEs prescribing cascade

KW - ADRs

KW - CKD

KW - Elderly

KW - Frailty

KW - Multimorbidity

KW - PIMs

KW - Polypharmacy

UR - http://www.scopus.com/inward/record.url?scp=85088458335&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85088458335&partnerID=8YFLogxK

U2 - 10.1007/978-981-15-2365-6_14

DO - 10.1007/978-981-15-2365-6_14

M3 - Chapter

AN - SCOPUS:85088458335

SN - 9789811523649

SP - 223

EP - 237

BT - Recent Advances of Sarcopenia and Frailty in CKD

PB - Springer Singapore

ER -

Polypharmacy and frailty in chronic kidney disease

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this